Kornimate/medical-research-clean huggingface dataset:
the effect of 0.5% roxithromycin lotion for androgenetic alopecia

Conditions: Alopecia

Summary: the purpose of this study is exploiting the new drugs for androgenetic alopecia because there are still no effective and safe topical drug for androgenetic alopecia. roxithomycin is one of the macrolide antibiotics that has immunomodulatory effects. we firstly found that roxithromycin increases the rate of murine and human hair follicle elongation in vitro. therefore, we apply this drug on this disease therapy.

the topical therapy for androgenetic alopecia is still not enough to improve cosmetically. thereforem we try to find new effective and safe topical therapy for this disease. roxithromycin has not only antibacterial action but also immunomodulatory and anti-inflamatory potency. for example, roxitromycin inhibits t cell responces to mitogens and production of cytokines, il-2 and il-5. we firstly found that roxitromycin increased human and murine hair elongation in vitro to inhibit apoptosis of hair bulb. then, we wish to apply roxithromycin on the therapy for androgenetic alopecia.

Eligibility criteria:
inclusion criteria: * androgenetic alopecia exclusion criteria: * cicatricial alopecia * allergy to roxitromycin * children (19years old or younger) * pregnant female

Keywords: androgenetic alopecia roxitromycin apoptosis
nurse leadership for hospital infection control

Conditions: Nurse's Role; Infection

Summary: the aim is to deliver an intervention to promote nurse leadership and decision-making in the hospital setting, by providing them with training for maintaining minimum service delivery standards for hospital infection control with respect to covid-19; but also other infectious disease burden management.

nurses are frontline practitioners in the fight against covid-19. empowering nurses through training for infection prevention for covid-19 is an essential step to facilitate nurse leadership and safety in the hospital. there is immense reliance on nurses with regard to patient safety, yet very little effort is made to invest in interventions for their leadership roles in developing countries, including pakistan. in this study the aim is to deliver an intervention for covid-19 preventive protocols to nurses and assess the impact of the intervention through a pre and post-test survey. a total of 200 nurses will be sampled. a 100 nurses each will be part of the control and experiment group each. the data will be analyzed using spss. pre and post test results will be presented using descriptive data and bivariate regression will be used to present higher odds of confidence in preventive and awareness literacy for covid-19 in nurses after intervention delivery. through this research the aim is to improve nurse leadership in maintaining minimum service delivery standards for hospital infection control with respect to covid-19; but also other infectious disease burden management.

Eligibility criteria:
inclusion criteria: * the selection criteria will be all currently working staff nurses. exclusion criteria: * student nurses or nurses not part of clinical rounds.

Keywords: randomized control trial nurse leadership hospital infection control covid-19
pain inhibitory effects of a single painful mechanical stimulus compared to multiple and multiple at different locations

Conditions: Healthy

Summary: the objective is to estimate the effects on pain thresholds of a single painful mechanical stimulus compared to multiple and multiple stimuli at different locations.

the mechanical stimulus produced in manual therapy (mt) techniques elicits neurophysiological responses within the peripheral and central nervous system responsible for pain inhibition. almost all types of mt elicit a neurophysiological response that is associated with the descending pain modulation circuit. but it has not been demonstrated whether this inhibition occurs through a conditioned pain modulation mechanism induced by painful mechanical stimulation that is carried out with manual therapy techniques.

Eligibility criteria:
inclusion criteria: * healthy male or female between 18 and 65 years * free of pain and with no history of chronic pain exclusion criteria: * pregnant or having given birth within the last year

Keywords: conditioned pain modulation manual therapy physiotherapy physical therapy
observational study to evaluate the efficacy and safety of novomix® 30 in type 1 and 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: this study is conducted in europe. this observational study is aimed to reflect the post-authorisation experience with insulin analogue (biphasic insulin aspart 30) when used under normal clinical practice conditions in serbia.


Eligibility criteria:
inclusion criteria: * type 1 or type 2 diabetes mellitus inadequately controlled on human insulin therapy lasting for at least 6 months * hba1c greater than 7% * informed consent exclusion criteria: * patients with a hypersensitivity to biphasic insulin aspart 30 or to any of the excipients * other limiting conditions specified in the locally approved novomix 30 spc ( summary of product characteristics), pil ( patient information leaflet). * women who are pregnant, breast feeding or have the intention of becoming pregnant within next couple of months
multicenter study to evaluate the clinical and cost effectiveness of a youth culturally adapted therapy (ycmap)

Conditions: Self Harm

Summary: to evaluate the clinical and cost-effectiveness of a youth culturally adapted manual assisted therapy (ycmap) in pakistani adolescents with a history of self-harm

globally suicide is the second leading cause of death in young people 15-29 years of age. a recent review indicated that the reported suicide rates in south asia are high compared to the global average. these figures are likely to be an under estimate since suicide data from many low and middle income countries (lmics) is lacking. there is little official data on suicide from pakistan, where suicide and self-harm remains as criminal act and socially, religiously condemned. however, there is accumulating evidence that both self-harm and suicide rates have been increasing in pakistan. this is the first rct of a psychological intervention for self-harm in children and young people in pakistan. it follows from the work of "multicentre rct to evaluate the clinical and cost effectiveness of culturally adapted manual assisted psychological intervention"(cmap) trial currently taking place in adults who have self-harmed in pakistan, by evaluating whether a similar intervention, adapted for children and adolescents, could be clinically and cost effective.

Eligibility criteria:
inclusion criteria: * patients age 12-18 years presenting to the participating gps, emergency departments or admitted after an episode of self-harm to the participating hospitals or self-referrals. * history of recent self-harm. recent self-harm is defined as self-harm occurring within the last 3 months (from the initial identification of a potential participant). * participants living within the catchment area of the participating practices and hospitals. * not needing inpatient psychiatric treatment. exclusion criteria: * severe mental illness (such as psychotic disorder) as self-harm commonly co- occurs with other mental health difficulties. * conditions limiting engagement with assessment or intervention, including developmental and communication disorders, intellectual disabilities and autistic spectrum disorders. * temporary resident unlikely to be available for follow up.

Keywords: self-harm, adolescents, adaptation, problem solving, lmics
interferon-α for tp53 myeloid malignancy post allo-hsct

Conditions: Myeloid Leukemia; Myelodysplastic Syndromes

Summary: to investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (aml) and myelodysplastic syndrome (mds) with tp53 mutation who were negative for minimal residual disease (mrd) by flow cytometry within 2 months after allogeneic hematopoietic stem cell transplantation. to explore the efficacy of interferon-α in reducing the relapse rate of aml/mds patients with tp53 mutation after allogeneic hematopoietic stem cell transplantation (allo-hsct).


Eligibility criteria:
inclusion criteria: 1. myelodysplastic syndrome (mds) diagnosed according to the 2022 international consensus classification of myeloid neoplasms and acute leukemia (2022icc) criteria, acute myeloid leukemia (aml) with tp53 mutation (unrestricted remission status), minimal residual disease (mrd) monitored by flow cytometry within 2 months after receiving the first allogeneic hematopoietic stem cell transplantation negative patients 2. male or female, aged 12-65 years 3. karnofsky score \>60, estimated survival time \>3 months 4. no history of severe graft-versus-host disease (gvhd), uncontrolled gvhd, or severe systemic organ dysfunction: 1. absolute neutrophil count (anc) greater than 0.5×109/l 2. creatinine \< 1.5mg/dl 3. cardiac ejection index \>55% 5. signed informed consent. exclusion criteria: 1. severe cardiac, renal, or liver dysfunction 2. combined with other malignant tumors requiring treatment 3. inability to understand or adhere to the study protocol due to clinical symptoms of brain dysfunction or severe mental illness 4. patients who are unable to complete the necessary treatment plan and follow-up observation 5. patients with severe acute anaphylaxis 6. clinically uncontrolled severe life-threatening infections 7. patients enrolled in other clinical trials 8. other reasons considered by the investigator to be inappropriate for clinical trial participants.

Keywords: ifn-α preventing relapse allo-hsct
combined pd1 inhibitor and decitabine in elderly patients with relapse and refractory acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: this is an open-label, single arm, phase 2 study to evaluate efficacy and safety of pd1 inhibitor camrelizumab(shr-1210) combined with dna methyltransferase inhibitor decitabine in elderly patients with relapse and refractory acute myeloid leukemia.

in this single-center, open-label, nonrandomized, no control, prospective clinical trial, 29 relapsed or refractory acute myeloid leukemia patients will be enrolled. patients will be administered camrelizumab(shr-1210) at d1 and d15 and decitabine at d1-5. treatment repeats every 28 days until disease progression or unacceptable toxicity.

Eligibility criteria:
inclusion criteria: * age: 60-75 * relapsed and refractory patients with acute myeloid leukemia via morphology and immunology * ecog：0-2 * life expectancy ≥ 3 months * adequate laboratory parameters during the screening period as evidenced by the following: 1. creatinine clearance≥30 ml/min and serum creatinine ≤ 160µmol/l 2. alt and ast ≤ 3 × upper limit of normal (uln) 3. fev1,fvc,dlco ≥ 50% predicted value 4. left ventricular ejection fraction (lvef) ≥ 40%, no symptomatic arrhythmia 5. able to understand and sign an informed consent form (icf). exclusion criteria: * treatment-related aml * allergic to camrelizumab, decitabine, other monoclonal antibody or pharmaceutical excipients * use of immunosuppressive drug within 2 weeks before entering the group * abnormal liver and kidney function(does not meet the inclusion criteria) * suffering from heart failure * active tuberculosis or hiv positive * active hepatitis: hepatitis b(hbsag positive and hbv dna≥500iu/ml), and hepatitis c(hcv rna positive, abnormal liver function) ,hepatitis b and hepatitis c infection in common. * active, known or suspected autoimmune disease. subjects who were in a stable state without systemic immunosuppressive therapy were admitted * concurrent medical condition requiring the long-term use of immunosuppressive medications, or immunosuppressive doses of systemic corticosteroids \> 10 mg/day topical prednisone or equivalent * suffer from other hematological neoplasm * known history of use other immune checkpoint inhibitor * other factors that may lead to the study termination, such as severe disease or abnormal laboratory tests or family or social factors affecting subjects safety or test data and sample collection.

Keywords: pd1 inhibitor dna methyltransferase inhibitor acute myeloid leukemia
digidiab evaluation domiciliary nursing care

Conditions: Type 2 Diabetes; Type 2 Diabetes Mellitus (T2DM); Type 2 Diabetes, Insulin Requiring

Summary: glucotab is a stand-alone software system to support healthcare professionals in the care of patients with diabetes mellitus or newly diagnosed hyperglycaemia who are treated with insulin and/or other glucose-lowering drugs or of patients only requiring glucose monitoring. it provides a therapy algorithm for subcutaneous basal insulin therapy of patients with type 2 diabetes, which will be used in this study.

glucotab: the ce-marked medical device glucotab is a system designed to support healthcare personnel in managing insulin therapy for patients with diabetes. in this study, only the glucotab algorithm supported basal therapy will be used, which is intended for patients with type 2 diabetes in domiciliary nursing care requiring insulin therapy. glucotab has a ce certificate, will be used according to its intended purpose and no additional burdensome or invasive interventions are planned

Eligibility criteria:
inclusion criteria: * informed consent obtained after being advised of the nature of the study * male or female aged ≥ 18 years * type 2 diabetes (treated with insulin therapy) * receiving domiciliary nursing care exclusion criteria: * type 1 diabetes mellitus * intravenous insulin therapy * hyperglycaemic episodes (ketoacidosis, hyperosmolar state) if they require intravenous insulin therapy * continuous subcutaneous insulin infusion * gestational diabetes or pregnancy * known or suspected allergy to insulin * total parenteral nutrition * any mental condition rendering the patient incapable of giving his/her consent * any disease or condition which according to the investigator would interfere with the trial or the safety of the patient
soluble factors in the serum of severely burned patients

Conditions: Burn Patients

Summary: the present study investigates the levels of certain soluble factors in the blood of patients with severe burn injury. serum levels of different soluble factors will be correlated with the clinical outcome, presence of sepsis, the area of burn, and other clinical parameters in order to make a statement regarding their use as biomarkers in the prediction and monitoring of burn patients.

burn patients still represent a critical patient collective with a high mortality rate although treatment technologies have improved over the years. one problem healthcare professionals face is the fact that reliable biomarker which predict the clinical outcome, the onset of sepsis, and monitor the severity of disease in burn patients are still missing. these biomarkers would allow an early adoption of treatment modalities to improve the outcome and prevent life-threatening complications. blood samples from severely burned patients will be collected over a period of five days and different cytokines (for example the macrophage migration inhibitory factor protein family) will be measured in the serum. clinical data of the patients (sepsis, total body surface area of burns, abbreviated burn severity index, sepsis-related organ failure assessment, etc.) will be documented and correlated to the levels of soluble factors.

Eligibility criteria:
inclusion criteria: * 18 years of age * minimum of 10% total body surface area burn * needing icu treatment exclusion criteria: * younger than 18 years of age * immunosuppression (e.g. hiv) * undergone surgery 2 weeks prior to burn injury * malignancies * severe diseases (myocardial infarction, lung embolism) * declining to participate in the study
chidamide in combination with carboplatin and paclitaxel in advanced non-small cell lung cancer

Conditions: Non-small-cell Lung Cancer

Summary: the purpose of this study is to evaluate the efficacy and safety of chidamide combined with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.

the study is to evaluate efficacy which includes the progression free survival (pfs), pfs at 6 months, objective response rate, duration of response rate, overall survival and time to progression, and safety which include adverse events, vital signs, laboratory tests, of the treatment of chidamide plus paclitaxel and carboplatin in patients with advanced non small cell lung cancer.

Eligibility criteria:
inclusion criteria: * patients with histology or cytology confirmed non-small-cell lung cancer,stage iiib or iv. newly diagnosed or relapsed after surgery but have not received systemic drug therapy.adjuvant chemotherapy after surgery should have completed for more than one year at study entry. * aged 18\~75 years * epidermal growth factor receptor (egfr) mutation negative or egfr status is unknown * with at least one measurable lesion * white blood cell count≥4×10\^9/l,platelet count≥100×10\^9/l and hemoglobin≥11g/l * life expectancy \>3 months * eastern cooperative oncology group performance status of ≤1 at study entry * women of childbearing age should have pregnancy test negative and would like to conduct birth control during the study * have signed informed consent exclusion criteria: * patients with clinically significant corrected qt interval prolongation, or ventricular tachycardia,or auricular fibrillation, or ≥grade 2 sino-auricular heart-block,or ≥grade 3 atrioventricular block,or myocardial infarction within one year, or congestive heart failure,or patients with symptomatic coronary disease which need to be treated by drug * the size of fluid area detected by cardiac ultrasonography in cavum pericardium is ≥10mm during diastolic period * organ transplant patients * patients with active bleeding or new thrombotic diseases * patients with body temperature \>38.5℃ for more than 3 days * total bilirubin \>1.5 fold of upper limit of normal (uln), alt/ast\>1.5 fold of uln or serum creatine \>1.5 fold of uln * patients with symptomatic brain-metastasis * pregnant or lactating women * patients with mental disorder

Keywords: chidamide,lung cancer
ethanol-lock treatment in preventing central venous catheter infections in patients with high-risk neuroblastoma

Conditions: Neuroblastoma

Summary: rationale: ethanol-lock treatment may help prevent central venous catheter infections in patients with high-risk neuroblastoma. purpose: this phase i trial is studying the side effects of ethanol-lock treatment in preventing central venous catheter infections in patients with high-risk neuroblastoma.

objectives: primary * determine the safety and tolerability of the ethanol-lock strategy (etl) in preventing central venous catheter infections in patients with high-risk neuroblastoma being treated on clinical trial mskcc-03077. secondary * determine whether this strategy increases the likelihood of remaining infection-free for 6 months. * determine the cumulative incidence of a single positive centrally-drawn blood culture in these patients and compare to previously obtained historical controls. * determine the median time-to-infection of the central line, where infection is defined as any positive centrally-drawn (from the treated line) blood culture. * determine the cumulative incidence of central line removals in these patients and compare to historical controls. * collate the types of organisms among these patients who develop a positive centrally-drawn blood culture and compare to historical controls. outline: this is a prospective, nonrandomized, open-label, historical control study. patients receive monoclonal antibody 3f8 on clinical trial mskcc-03077. in each course of monoclonal antibody 3f8 treatment, patients receive ethanol-lock treatment on days 0-3 (after each monoclonal antibody 3f8 infusion) for up to 6 months for central venous catheter management. projected accrual: a total of 50 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of neuroblastoma by histopathology or bone marrow metastases and high urine catecholamine levels * high-risk disease * currently enrolled on clinical trial mskcc-03077 * expected duration of therapy ≥ 6 months * surgically-implanted central venous catheter with documented patency * must be able to establish patency of central venous catheter lumen * no history of culture-positive central venous catheter infection in catheter to be treated patient characteristics: * bilirubin \< 1.5 times upper limit of normal (uln) * ast and alt \< 2.5 times uln * alkaline phosphatase \< 2.5 times uln * no history of hypersensitivity to ethanol * no history or documented active seizure disorder * no documented acute liver failure prior concurrent therapy: * see disease characteristics * no concurrent total parenteral nutrition or other infusion requiring use of the central line at night * no concurrent levetiracetam or other anticonvulsants

Keywords: disseminated neuroblastoma localized unresectable neuroblastoma recurrent neuroblastoma regional neuroblastoma stage 4s neuroblastoma
telehealth treatment for opioid use disorders

Conditions: Opioid Use Disorder

Summary: this study aims to use an opioid use disorder (oud) telehealth platform to reduce overdose events. this telehealth platform will be pilot tested to evaluate its preliminary efficacy in terms of motivating engagement in medications for oud (moud), as well as its feasibility, acceptability and satisfaction to both first responders/providers and participants.

the primary objective of the study is to assess effects of enrollment in a comprehensive telehealth platform, in adults with moderate or severe opioid use disorder with a history of at least one opioid overdose. thirty adults with moderate or severe opioid use disorder with a history of at least one opioid overdose will be enrolled and the primary endpoint will be attendance at first appointment for medication for opioid use disorder at 30 days. secondary aims include assessing engagement in the first moud appointment at 90 days and self-report of the number of subsequent overdose events at 30 and 90 days. exploratory aims include feasibility of intervention, readiness and intention to engage in treatment, acceptability and satisfaction of intervention, and comparison of moud engagement with data from previous in-person studies.

Eligibility criteria:
inclusion criteria: * can speak, read and write in english * provision of signed and dated informed consent form * have a history of at least one opioid overdose * screened positive for oud, moderate or severe, based on the diagnostic and statistical manual-5th edition * have a working cell phone number and working device that can access a web browser and receive texts (i.e., smartphone, tablet or computer) or be willing to use a device provided by the study team * can provide a working email address or be willing to create one exclusion criteria: * current use of buprenorphine, methadone, or naltrexone for a substance use disorder * pregnancy or lactation * known current suicide risk based on participant self-report * on parole or incarcerated at time of enrollment based on participant self-report

Keywords: harm reduction medication for opioid use disorder